



**21 July 2021**

## **Issue of New Shares**

NEW YORK and SYDNEY, Australia, July 21, 2021 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), wishes to advise shareholders that the Company has completed the issue of 13,250,000 options exercisable expiring 30 June 2024 to the Directors. Details of the options were disclosed in Notice of Annual General Meeting released to the NSX on 15 June 2021.

Shareholders approved the issue of shares at the Annual General Meeting held on 16 July 2021.

-End-

### **About Beroni Group Limited**

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit [www.beronigroup.com](http://www.beronigroup.com).

Mr Jacky Zhang  
Executive Chairman  
Tel: +86 1851 6931 911  
E: [jacky.zhang@beronigroup.com](mailto:jacky.zhang@beronigroup.com)

Mr Peter Wong  
Executive Director & CFO  
Tel: +61 423 727 580  
E: [peter.wong@beronigroup.com](mailto:peter.wong@beronigroup.com)